The Economic Impact of Switching to Trastuzumab Biosimilar for the Treatment of Metastatic Breast Cancer from a Chinese Payer Perspective
Sep 1, 2018, 00:00 AM
10.1016/j.jval.2018.07.018
https://www.valueinhealthjournal.com/article/S1098-3015(18)32374-X/fulltext
Section Title :
Section Order :
150
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)32374-X&doi=10.1016/j.jval.2018.07.018